UTHR — UNITED THERAPEUTICS Corp

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1082554 ·
Last close
$475.45
Market Cap
$20.39B
52W High
$609.35
52W Low
$409.07
ADV30
640,120
Next earnings
2026-10-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 783,300,000 683,800,000 330,800,000 333,000,000 7,220,100,000 1,803,200,000 819,800,000
Mar 2026 781,500,000 648,100,000 325,800,000 274,900,000 6,714,200,000 1,279,700,000 813,100,000
Dec 2025 790,200,000 686,800,000 357,500,000 364,300,000 7,880,000,000 1,557,100,000 783,800,000
Sep 2025 799,500,000 698,600,000 389,300,000 338,700,000 7,351,100,000 1,340,100,000 760,900,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,685,200,000
Investing CF
$744,500,000
Financing CF
$-2,219,600,000
CapEx
$-597,700,000
Dividends Paid
—
Buybacks
$-2,554,900,000
EPS Diluted TTM
$27.95
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$9,164,800,000
Inventory
$193,800,000
Receivables
$310,300,000
ST Investments
$859,100,000
EBIT TTM
$1,585,000,000
Pretax Income TTM
$1,573,000,000
Interest Exp TTM
$12,000,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,154,500,096
EBITDA
$1,496,199,936
Free Cash Flow
$557,137,472
Enterprise Value
$18,659,092,480
Total Cash
$2,662,299,904
Total Debt
$0
Shares Out
42,890,692
Trailing EPS
$27.89
Book Value
$149.97
ROE
19.3%
ROA
11.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 3,182,700,000 1,517,200,000 1,334,700,000 7,880,000,000 783,800,000 7,096,200,000 1,561,200,000
Dec 2024 2,877,400,000 1,448,100,000 1,195,100,000 7,364,000,000 920,000,000 6,444,000,000 1,327,100,000
Dec 2023 2,327,500,000 1,184,900,000 984,800,000 7,167,000,000 1,182,200,000 5,984,800,000 978,000,000
Dec 2022 1,936,300,000 979,700,000 727,300,000 6,044,500,000 1,247,800,000 4,796,700,000 802,500,000

TTM Snapshot

Revenues TTM
$2,668,700,000
NetIncome TTM
$1,138,200,000
OpCashFlow TTM
$0
Assets (Latest)
$7,880,000,000
Forward EPS
$30.03

Max Pain — expiry 2026-10-16

max pain strike: $520.00 · spot: $474.82 · call oi: 18,082 · put oi: 18,136

Peers — same industry

TickerNameMarket CapLastDaily %
VTRS Viatris Inc $20.48B $17.83 —
GMAB GENMAB A/S $21.72B $35.32 —
INSM INSMED Inc $25.73B $117.83 —
ROIV Roivant Sciences Ltd. $25.86B $35.80 —
RPRX Royalty Pharma plc $25.92B $58.21 —

News headlines (Yahoo Finance, 1h cache)

What United Therapeutics (UTHR)'s Goldman Sell Call Amid Bold Pipeline And Buyback Means For Shareholders
2026-09-27 19:10 · Yahoo
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions
2026-09-25 10:02 · Yahoo
Why United Therapeutics (UTHR) Shares Are Falling Today
2026-09-25 01:12 · Yahoo
Biotech Options Buzz: UTHR, NMRA, EWTX
2026-09-18 15:46 · Yahoo
1 Cash-Heavy Stock to Target This Week and 2 We Question
2026-09-11 18:51 · Yahoo
United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace?
2026-09-11 00:21 · Yahoo
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
2026-09-08 11:00 · Yahoo
Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio
2026-09-08 08:31 · Yahoo
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
2026-09-04 15:30 · Yahoo
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
2026-09-03 15:43 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.